AKT1 and hepatocellular carcinoma: Considering the rapid increase in the incidence of HCC worldwide and the limited choice of actual therapeutic options, the development of novel targeted PI3K/Akt pathway drugs with low dosages, weak toxicity, and significant therapeutic effects is not only the focus of current clinical practice but also the focus of future therapeutic development.